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ABSTRACT: Emerging evidence indicates that G-protein coupled receptor 55 (GPR55), a nonclassic receptor of the
endocannabinoid system that is activated by L-a-lysophosphatidylinositol and various cannabinoid ligands, may
regulate endocrine function and energy metabolism. We examined how GPR55 deficiency and modulation affects
insulin signaling in skeletal muscle, adipose tissue, and liver alongside expression analysis of proteins implicated in
insulin action and energy metabolism. We show that GPR55-null mice display decreased insulin sensitivity in these
tissues, as evidenced by reduced phosphorylation of PKB/Akt and its downstream targets, concomitant with increased
adiposity and reduced physical activity relative towild-type counterparts. Impaired tissue insulin sensitivity coincided
with reduced insulin receptor substrate-1 abundance in skeletal muscle, whereas in liver and epididymal fat it was
associatedwith increased expressionof the 3-phosphoinoistide lipidphosphatase, phosphatase and tensinhomolog. In
contrast,GPR55activationenhancedinsulinsignaling inculturedskeletalmusclecells, adipocytes,andhepatocytes; this
responsewasnegatedby receptor antagonists andGPR55gene silencing inL6myotubes.SustainedGPR55antagonism
in 3T3-L1 adipocytes enhanced expression of proteins implicated in lipogenesis and promoted triglyceride accumula-
tion. Our findings identify GPR55 as a positive regulator of insulin action and adipogenesis and as a potential thera-
peutic target for countering obesity-induced metabolic dysfunction and insulin resistance.—Lipina, C., Walsh, S. K.,
Mitchell,S.E.,Speakman, J.R.,Wainwright,C.L.,Hundal,H.S.GPR55deficiency isassociatedwith increasedadiposity
and impaired insulin signaling in peripheral metabolic tissues. FASEB J. 33, 1299–1312 (2019). www.fasebj.org
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Pathologic over activation of the endocannabinoid system
(ECS) is associated with the development of dyslipidemia,
obesity, and type II diabetes mellitus (1–4). Indeed, the ECS
can act centrally and peripherally to regulate a number of
metabolic processes, including feeding behavior (5), energy
expenditure(6,7),andnutrientuptakeandmetabolism(8–10).
KeyECScomponents includetheG-proteincoupledreceptors
cannabinoid receptor (CB)1 and CB2 and their endogenous
lipid ligands anandamide and 2-arachidonylglycerol, collec-
tively known as endocannabinoids (11–14). Modulation of
these receptors has been shown to promote significant alter-
ations in body weight and various metabolic parameters in
rodents and humans (15, 16). More specifically, CB1 receptor
activation can result in insulindesensitizationandsuppressed
metabolic activity, whereas inhibition of this same re-
ceptor has been shown to attenuate suchmanifestations
of obesity-induced metabolic syndrome (6, 10, 17, 18).
In addition to activating CB1 and CB2, some cannabi-
noids (termed atypical cannabinoids) can promote cellu-
lar responses by acting through non-CB1/CB2 receptors
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such as the G-protein coupled receptor 55 (GPR55) (19).
GPR55 is considered by some as a third member of the
cannabinoid receptor family. However, this issue remains
contentious because GPR55 shares little amino acid iden-
tity (;14%) and lacks the classic “cannabinoid binding
pocket” present in CB1 and CB2 (20). Nonetheless, the
action of atypical cannabinoids at GPR55 has attracted
significant attention because the receptor is expressed
widely within the body but also because of evidence
linking GPR55 modulation to regulation of diverse phys-
iologic and pathologic processes, including endocrine
function, tissue inflammation, and energy metabolism
(21–23). For example, 5-methyl-4-[(1R,6R)-3-methyl-6-(1-
cyclohexen-1-yl]-1,3-benzenediol (O-1602) and abnormal
cannabidiol, 2 potent syntheticGPR55 agonists, have been
shown to promote insulin secretion fromBRIN-BD11 cells
and isolated mouse islets and exert a glucose lowering
effect in vivo (24), a response partly blunted in islets from
GPR55-deficient mice (25). In rats, chronic O-1602
administration reduces adipocyte expression of genes
encoding lipolytic enzymes, consonant with an observed
increase in adiposity (26). Sustained in vitro incubation of
adipocytes with O-1602 enhances intracellular lipid accu-
mulation, suggesting that the increased adiposity trig-
gered by O-1602 in rodents may be driven by direct
effects of the compound on adipose tissue (26).
Although atypical cannabinoids may promote some of
the above responses via GPR55, the primary physiologic
ligand for this receptor is thought to be an endogenous
bioactive lipid called lysophosphatidylinositol (LPI) (27).
GPR55 is also activated by oleoylethanolamide and
palmitoyl-ethanolamine, which, like anandamide, are
fatty acid amides, raising the possibility that GPR55
may function as a lipid-sensing receptor. LPI and
oleoylethanolamide promote insulin release from iso-
lated mouse islets (24, 28), and in humans modulation
of the LPI/GPR55 system has been positively linked
with increased obesity by poorly understood mecha-
nisms (29). The significance of GPR55 as a potential
regulator of insulin action and energy homeostasis is
further strengthened by the finding that GPR552/2
mice exhibit insulin resistance and increased adiposity
(30). Skeletal muscle, adipose tissue, and liver represent
principal targets for insulin action, but it is unknown
whether GPR55 influences insulin action in these tis-
sues or whether the insulin resistance observed in
GPR552/2 mice are a consequence of impaired insulin
action in these key metabolic tissues. The studies re-
ported herein explore how GPR55 deficiency affects
insulin action in skeletal muscle, adipose tissue, and
liver and examine whether modulation of GPR55 in
cultured cells that serve as empirical models of these
tissues exhibit changes in insulin signaling in vitro.
MATERIALS AND METHODS
Bovine insulin and LPI were purchased from MilliporeSigma
(Burlington, MA, USA). O-1602 and O-1918 were from Tocris
Bioscience (Abingdon, United Kingdom). Anti–insulin re-
ceptor substrate 1 (IRS-1) and phosphatase and tensin homolog
(PTEN) antibodies were from Santa Cruz Biotechnology
(Dallas, TX, USA). Antibodies to phospho-CREB (Ser133),
phospho-ERK1/ERK2 (Thr202/204), phospho-PKB/Akt (Thr308),
phospho-PKB/Akt (Ser473), phospho–glycogen synthase
kinase-3 (GSK3)a/b (Ser21/9), phospho-FoXO1 (Thr24)/FoXO3a
(Thr32), native PKB/Akt, phosphoinositide dependent kinase-1
(PDK1), FAS, perilipin, fatty acid binding protein 4 (FABP4),
peroxisome proliferator-activated receptor-g (PPARg), Rho ki-
nase 1 (ROCK1), myosin phosphatase targeting protein1
(MYPT1), and phospho-MYPT1 (Thr696) were from Cell Signal-
ing Technology (Beverly, MA, USA). Antibodies for PGC-1a
andthe insulin receptorb-subunitwere fromAbcam(Cambridge,
United Kingdom) and Merck-Millipore (Darmstadt, Germany),
respectively. Anti-actin and a-tubulin antibodies were fromMil-
liporeSigma. Horseradish peroxidase (HRP)-conjugated anti-
rabbit IgG and anti-mouse IgG were from New England Biolabs
(Beverley,MA,USA).Theantibody targeting the catalytic subunit
of protein phosphatase 2A was generated by the Division of
Signal Transduction Therapy (University of Dundee, Dundee,
United Kingdom). All primers were synthesized by our in-house
Oligonucleotide Synthesis Service.
Animals
Homozygous GPR552/2 mice were generated by intermating
heterozygousGPR55+/2mice and genotyping the F1 progeny as
previously described (31). Male wild-type (WT) C57BL/6J and
GPR552/2mice were maintained in the University of Aberdeen
Medical Research Facility at 216 2°C on a 12 h light/dark cycle
with ad libitum access to food (CRM; Special Diets Service, Essex,
United Kingdom) andwater. All studies were in accordwith the
ARRIVE guidelines (32) and performed in line with the UK An-
imals (Scientific Procedures) Act 1986.
Body composition, temperature, physical activity,
and metabolic parameters
Analysis of various body parameters was carried out from 10 to
22 wk of age in male WT and GPR552/2 mice. Fat and lean
mass were analyzed using echo resonance scanning (EchoMRI
Whole Body Composition Analyzer; EchoMRI LLC, Houston,
TX, USA) and expressed as percentage of body weight. For
analysis of core body temperature and physical activity, trans-
mitters were implanted intraperitoneally at 3 mo of age. Mice
were allowed a 3–4wk recovery period prior to data acquisition.
Home cages were placed onto transponder energizers (ER-4000
Receiver; MiniMitter, Bend, OR, USA), allowing noninvasive
monitoring of body temperature and physical activity through-
out the study period. The VitalView Data Acquisition System
(MiniMitter) collected data at 1-min intervals.
Energy expenditure, resting metabolic rate, and respirometry
quotientwere determined in 4-mo-oldmice by indirect calorimetry
using an Oxymax Deluxe System (Columbus Instruments, Co-
lumbus, OH, USA). Measurements were taken over 4 d, with d 1
data disregarded to allow for acclimatization. Airflow was main-
tained at 0.5 L/min with ambient temperature of 216 1°C. Read-
ings were taken over 10-min cycles at 2-min intervals (90 s with a
30 spurge) fromeachchamberplusa referenceair sampleper cycle.
Blood sampling and tissue harvesting
In some experiments, blood glucose and plasma triglyceride
concentrations were determined in unfed (6 h) mice using a
glucometer (OneTouchUltra BloodGlucoseMonitoring System;
Johnson and Johnson’s, High Wycombe, United Kingdom) or
Triglyceride Quantification Kit (Abcam). Plasma insulin levels
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were measured using a Mouse Insulin ELISA Assay (Mercodia,
Uppsala, Sweden). WT and GPR552/2 mice were also studied
postprandially. Animals were anesthetized with a mixture of
ketamine (120 mg/kg) (Vetalar; Pfizer, Dublin, Ireland) and
xylazine (16 mg/kg) (Rompun; Bayer, Dublin, Ireland) via in-
traperitoneal injection, followedby an intraperitoneal injectionof
insulin (2 mU/g) or vehicle (control) solution 10 min prior to
collection of blood via cardiac puncture. Immediately upon
culling, blood was sampled for glucose and tissues [skeletal
muscle (gastrocnemius and soleus), white adipose tissue (epi-
didymal, retroperitoneal, subcutaneous, omental, mesemteric),
brown adipose tissue, and liver] were carefully excised, snap
frozen in liquid nitrogen, and stored at 280°C. Whole blood
containing heparin (20 U/ml final concentration) was centri-
fuged at 8000 g for 5 min at room temperature, after which the
plasma supernatant was collected and stored at280°C.
Cell/tissue processing and analysis
Rat L6 myotubes, humanmyoblasts, murine 3T3-L1 adipocytes,
rat H4IIE, and humanHepG2 hepatoma cell lines were cultured
and prepared for RNA extraction, RT-PCR, real-time quantita-
tive PCR (qPCR), and immunoblot analysis as previously de-
scribed (33–35). In some experiments, GPR55 was silenced in L6
muscle cells using a lentiviral short hairpin RNA (shRNA)
strategy as previously described (34, 35). Forward and reverse
oligonucleotides for rat GPR55 shRNA were: forward, 59-CCG-
GGGAAGCATCCCCATCTACACTCTCGAGAGTGTAGATG-
GGGATGCTTCCTTTTTG-39; reverse, 59-AATTCAAAAAGG-
AAGCATCCCCATCTACACTCTCGAGAGTGTAGATGGGG-
ATGCTTCC-39 (hairpin sequences are underlined). To silence
expression of GPR55 in 3T3-L1 adipocytes, cellswere transfected
with 50 nM of small interfering RNA (siRNA) for GPR55
(On-TargetPlus SmartPool; Dharmacon, Lafayette, CO, USA)
or 50 nM of control siRNA (On-TargetPlus Nontargeting
Control siRNA; Dharmacon) using JetPrime PolyPlus Trans-
fection reagent according to manufacturer’s instructions. A
list of primers used for qPCRandRT-PCRanalysis is provided
in Table 1.
Animal tissueswere prepared for immunoblot analysis using
antibodies against proteins of interest as previously described
(34, 35). Primary antibody detection was carried out using anti-
rabbit IgG-HRP or anti-mouse IgG-HRP–linked antibody (New
England Biolabs) as appropriate by ECL. Resulting band in-
tensities were quantified using ImageJ software (National Insti-
tutes of Health, Bethseda, MD, USA).
Statistical analysis
Data were analyzed using GraphPad Prism (GraphPad, La
Jolla, CA, USA). Statistical analysis was performed using
one- or two-way ANOVA (with Bonferroni post hoc test) or
unpaired Student’s t test as appropriate and considered sta-
tistically significant at P , 0.05. ANCOVA was performed
with body mass included as a covariate for analysis of energy
expenditure (36).
RESULTS
GPR55 deficiency in vivo is associated with
increased weight gain, adiposity, and
reduced physical activity
Toexplore the impact ofGPR55on insulinaction in tissues
with a key role in whole body fuel metabolism, it was
important to establish that GPR55 is expressed in skeletal
muscle, adipose tissue, and liver. qPCR analysis revealed
that GPR55 mRNA was present in all 3 tissues from WT
animalsbutnot in those fromGPR552/2 (KO)mice (Fig.1A).
GPR552/2mice display no overt metabolic phenotype
until 10 wk of age, after which they show a significant in-
crease in body mass compared with WT animals (Fig. 1B)
that cannot be attributed to increased energy (food) intakeor
changes in cyclical day/night body temperatures over the
10–22 wk age period (Fig. 1C, D). Analysis of physical ac-
tivity revealed that GPR552/2 mice exhibit a significant
(22%) reduction in total daily activity relative toWT animals
(Fig. 1E). Oxymax indirect calorimetry indicated no notable
differences in restingmetabolic rate or respirometryquotient
betweenWT and GPR552/2mice (data not shown), but, in
linewith thereducedphysicalactivity,energyexpenditureof
GPR552/2 mice was significantly lower during the dark
phase,aperiodwhenmicearenormallymostactive (Fig.1E).
WT and GPR552/2 mice were subjected to EchoMRI
analysis at 22 wk of age, and the latter exhibited a signif-
icant increase in total body fat,whichwas accompaniedby
a small but significant reduction in lean mass (Fig. 2A, B).
Analysis of total protein content expressed per milligram
wet weight of gastrocnemius muscle indicated a modest
(;6%) reduction compared with WT muscle, although
this failed to reach statistical significance (Fig. 2C). Con-
sistent with the EchoMRI data, dissection of different fat
depots confirmed significant increases in epididymal,
retroperitoneal, subcutaneous, and mesenteric fat pad
mass, whereas omental and brown fat depots were un-
altered (Fig. 2D). To assess whether increased fat de-
position in GPR552/2 mice was underpinned by an
augmented lipogenic drive,we assessed expression of key
TABLE 1. List of primers used for RT-PCR and qPCR analysis
Primer, 59–39
Gene Species Application Sense Antisense
GPR55 Mouse RT-PCR CTATCTACATGATCAACTTGGCTGTT TGTGGCAGGACCATCTTGAA
GPR55 Mouse qPCR CCATATCCCCACCTTCCTCC CACTCCACCAGAGTGCAGAA
GPR55 Rat RT-PCR TCACCATCTGCTTCATCAGC CCTTACCAGGAACTGCAGGA
GPR55 Human RT-PCR TGGGCCTCTAAGAACCACAG CCGTCCCTCCCTACATGATC
FABP4/aP2 Mouse qPCR GCGTGGAATTCGATGAAATCA CCCGCCATCTAGGGTTATGA
Fasn Mouse qPCR CAGCCTCCTAAGCCAGGAG CCTCCACAGACAGGAAGATAGG
PPARg Mouse qPCR ATGCCAAAAATATCCCTGGTTTC GGAGGCCAGCATCGTGTAGA
18S rRNA Mouse qPCR CAGCCACCCGAGATTGAGCA TAGTAGCGACGGGCGGTGTG
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lipogenic markers. Figure 2E shows that expression of
FAS, perilipin, FABP4, and PPARg was significantly ele-
vated in GPR552/2 epididymal fat. We detected a signif-
icant increase in liver FAS abundance in GPR552/2mice
(Supplemental Fig. 1), potentially reflecting that these an-
imals may exhibit hepatic steatosis.
GPR552/2 mice display dysfunctional insulin
signaling in adipose tissue, liver, and
skeletal muscle
Recent work has shown that GPR55-deficient mice of
similar age to those used in this study are insulin resistant
given that they display impaired systemic insulin sensi-
tivity as judged on the basis of insulin tolerance analysis
(30).However, this latter studydidnot examine the effects
of GPR55 loss on insulin action in peripheral metabolic
tissues. Consistent with the insulin resistance reported
in these animals, GPR552/2 mice held without food for
6 h exhibit modest but significant hyperglycemia and
hypertriglyceridemia (Fig. 3A). In addition, GPR552/2
mice also display slightly increased fastingplasma insulin
levels, although the difference was not significant com-
pared with control WT animals (Fig. 3A). For analysis of
tissue insulin action, prandial animals were acutely ad-
ministered an intraperitoneal saline or insulin injection
before culling, and blood and tissues were harvested
10 min postinjection. Analysis of blood glucose indicated
that WT animals show a rapid reduction in blood glu-
cose during the 10 min postinsulin treatment period
(Fig. 3B). In contrast, although there was a tendency for
blood glucose to be lowered in insulin-treated GPR552/2
mice during this acute postinjection period, this reduc-
tion did not achieve statistical significance, further sup-
porting the idea that these animals exhibit impaired
insulin responsiveness.
Because adipose tissue, liver, and skeletal muscle
represent major sites for insulin-mediated glucose
disposal/metabolism, we assessed how insulin signal-
ing in these tissues may be affected using PKBThr308
phosphorylation as readout. Insulin induced a 3.3-, 4.8-,
4.9-, and 2.4-fold increase in PKB phosphorylation
in adipose tissue, liver, gastrocnemius, and soleus
muscles of WT mice, respectively (Fig. 4). However,
the acute response to insulin in these tissues from
Figure 1. Comparison of food intake and energy expenditure in WT and GPR55-deﬁcient (KO) mice. A) GPR55 mRNA
expression quantiﬁed relative to that of 18S rRNA in epididymal fat tissue, liver, and gastrocnemius muscle of WT and GPR55 KO
mice (n = 4/group). B–E) Body weight (B) and daily food intake (C) for WT and GPR55 KO mice were monitored over a 12-wk
period. Body temperature (D), physical activity and energy expenditure (E) for WT and GPR552/2 mice were determined along
with average values in the light phase (LP) and dark phase (DP). All values presented are the means 6 SEM from 12 mice unless
indicated otherwise. Asterisks denote statistically signiﬁcant differences between WT and GPR552/2 mice. *P , 0.05.
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GPR552/2 mice (Fig. 4) was significantly lower by 80%
(fat), 88% (liver), 55% (gastrocnemius), and 49% (soleus).
PKB is also phosphorylated on Ser473 and, as with Thr308
phosphorylation, phosphorylation of this site was also
significantly impaired in GPR55-deficient tissue (Sup-
plemental Fig. 2). The reduced PKB phosphorylation/
activation will have important consequences for regu-
lation of its downstream targets, such as Forkhead box
protein O1 (FOXO1) and GSK3, whose diminished
phosphorylation (Fig. 4A, B) enhances FOXO-mediated
gene transcription in adipose tissue and sustains in-
hibition of glycogen synthase by GSK3 in liver and
skeletal muscle.
GPR55 deficiency induces tissue specific
changes in PTEN and IRS-1 expression
To understand what may account for the reduced in-
sulin signaling capacity in adipose tissue, liver, and
skeletal muscle, we investigated the effects of GPR55
deficiency on the expression of molecules regulat-
ing proximal insulin signaling. There were no differ-
ences in insulin receptor (IRb), IRS-1, PDK1, or protein
phosphatase 2A (which can dephosphorylate PKB)
abundance in adipose tissue or liver, but expression
of PTEN (a 39-phosphoinostide phosphatase) was in-
creased in both tissues (Fig. 5A,B). PTENwas unaltered
Figure 2. GPR55-deﬁcient mice exhibit increased body fat mass and enhanced lipogenic drive. A, B)Mean fat (A) and leanmasses (B) forWT
and GPR55 KO mice at 22 wk of age were determined (n = 10 for WT, n = 8 for KO). C, D) Comparison of total protein content (per mg of
muscle tissue) in gastrocnemius muscle (n = 6 for each group) (C) and mean fat depot mass (D) for brown adipose tissue (BAT), epididymal
fat (Epi), retroperitoneal fat (Retro), mesenteric fat (Mesen), omental fat (Omen), and subcutaneous fat (Sub Cut) in WT and GPR552/2
mice are presented (n = 12 for each group). E) Protein lysates prepared from epididymal fat tissue of WT and GPR552/2 mice were
immunoblotted using the antibodies indicated (4 individual animals/group). NS, not signiﬁcant. Values presented aremeans6 SEM. *P, 0.05.
Figure 3. GPR55-deﬁcient mice display elevated circulating blood glucose and plasma triglyceride levels. A) Blood glucose (n = 12
for each group), fasting plasma insulin (n = 5 for each group), and plasma triglyceride (n = 4 for each group) concentrations
were determined in WT and GPR552/2 mice held without food for 6 h. B) Prandial blood glucose levels (n = 3 for each group)
were measured in WT and GPR55-deﬁcient mice treated with or without insulin (2 mU/g body weight for 10 min). *P , 0.05.
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in gastrocnemius muscle, which, by contrast, exhibits
significant reduction in IRS-1 protein abundance
(Fig. 5C).
Effects of GPR55 modulation in L6 myotubes,
3T3-L1 adipocytes, and H4IIE liver cells on
insulin action and lipogenic markers
Because GPR55 deficiency is associated with impaired
insulin signaling in skeletal muscle, adipose tissue, and
liver, we assessed if GPR55 was expressed in clonal cell
linesderived fromthese tissuesand, if so,whether receptor
activationmodulates insulin-dependent signaling. GPR55
was expressed in rat soleus muscle, L6, and human myo-
tubes (Fig. 6A–C). GPR55mRNAwas barely detectable in
L6 myoblasts (Fig. 6A), suggesting that receptor expres-
sion was likely to be differentiation linked in skeletal
muscle. Pretreatment of differentiated L6 myotubes with
LPI increasedGPR55mRNA, indicating that expression of
GPR55 is regulated in response to its ownactivating ligand
(Fig. 6C).
As expected, insulin stimulated both the MAP kinase
pathway (;4-fold) and PKB/Akt as judged by phos-
phorylation of ERK1/2Thr202/Thr204 and that of CREBSer133
(which lies downstream of ERK-directed signaling) and
PKB in L6myotubes (Fig. 6D,E). Phosphorylation of these
molecules by insulin was further enhanced if myotubes
were pretreated withO-1602 and LPI (2 GPR55 agonists).
Although neither agonist alone had a detectable effect
on PKB phosphorylation, the ability of both ligands to
enhance phosphorylation of this kinase by insulin was
negated if cells were cotreated with O-1918, a known an-
tagonist at GPR55 and GPR18 (Fig. 6D) (37).
Given the complex pharmacology of GPR55 and the
possibility thatO-1918mayalso act atGPR18,we assessed
the effects of applying structurally unrelated, but selective,
Figure 4. GPR55 deﬁciency is associated with impaired insulin signaling in peripheral tissues. Lysates prepared from epididymal
fat tissue (A), liver (B), gastrocnemius muscle (C), and solei (D) of WT and GPR552/2 mice stimulated with or without insulin
(2 mU/g body weight for 10 min) were immunoblotted using the antibodies against phospho (Thr308) and native PKB, FOXO,
GSK3, and a-tubulin as shown. Values presented are the mean 6 SEM from 5 individual animals. *P , 0.05.
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GPR55 antagonists N-[4-[[(3,4-dimethyl-5-isoxazolyl)
amino]sulfonyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-
quinolinecarboxamide (ML-193) and 4-[4,6-dihydro-4-(3-
hydroxyphenyl)-3-(4-methylphenyl)-6-oxopyrrolo[3,4-
c]pyrazol-5(1H)-yl]benzoic acid (CID16020046) (38). As
withO-1918, cotreatment of L6myotubeswithML-193 or
CID16020046 blocked the increase in insulin-stimulated
PKB phosphorylation in response to LPI (Fig. 7A, B). To
further substantiate that these effects were indeed medi-
ated via GPR55, receptor expression was stably silenced
in L6 myotubes using a lentiviral-based shRNA strat-
egy that significantly reduced GPR55 mRNA by ;80%
(Fig. 7C). Cells infected with a nontarget shRNA control
exhibited the archetypal insulin dependent phosphoryla-
tion of PKB, which was further enhanced by pretreatment
of cells with LPI. In contrast, although GPR55-depleted
myotubes display a modest reduction in PKB activation/
phosphorylation by insulin, they are no longer responsive to
LPI (Fig. 7D) or to ML-184, a strong GPR55 agonist (39) that
mimics the LPI response in controlmyotubes but not in those
inwhich the receptorhasbeen silenced (Fig. 7E). The failureof
LPI or ML-184 to augment insulin-mediated PKBS473 phos-
phorylation in GPR55-depleted myotubes also excludes the
possibility of GPR18 involvement. The modest decline in
insulin-stimulated PKB phosphorylation that we observe in
the GPR55 knockdown cells (Fig. 7D) may be explained, in
part, by an attendant decline in IRS-1 abundance (Fig. 7F)
and is consistentwithour finding thatmuscleofGPR552/2
mice also exhibit a reduction in IRS-1 content compared
with WT muscle (Fig. 5C).
In addition to culturedmyotubes,we can detectGPR55
expression in murine 3T3-L1 adipocytes, rat H4IIE liver
cells, and humanHepG2 liver cells (Fig. 8). As inmyotubes,
we find prior treatment of 3T3-L1 adipocytes, H4IIE, and
HepG2 liver cellswithLPI also enhanced insulin-dependent
PKBphosphorylation; this responsewas effectively negated
by cotreatment with the selective GPR55 antagonists
CID16020046 (40) and/or ML-193 (Fig. 8).
We cannot exclude the possibility that the increased
adiposity seen inGPR552/2micemaybea consequenceof
a direct loss in GPR55 action in adipose tissue rather than
being linked to changes in central “brain-driven” func-
tions. To explore this issue further, cultured 3T3-L1 adi-
pocytes were chronically exposed to ML-193 during the
course of a 10 d differentiation period to mimic a state
of sustained GPR55 inactivity/deficiency. Analysis of
key lipogenic markers revealed that, compared with cell
cultures treated with the control vehicle solution, those
chronically exposed to a selective GPR55 antagonist dis-
play elevated expression of genes encoding PPARg,
FASN, and FABP4 (Fig. 9A). This ML-193–induced in-
crease in lipogenic gene expression was associated with a
significant increase in the cellular abundance of perilipin,
FAS, acetyl CoA carboxylase, and FABP4 (Fig. 9B). The
observed increase in these lipogenic/adipogenic protein
markers would support greater fat accumulation, and, in
line with this idea, we observed a significant increase in
adipocyte triglyceride content in adipocytes treated with
ML-193 (Fig. 9C). Consistent with these ML-193–induced
responses, silencing GPR55 using siRNA (leading to
;70% reduction in GPR55 mRNA abundance) (Fig. 10A)
similarly promotes significantly enhanced FAS and
PPARg (Fig. 10B, C) mRNA levels during adipocyte dif-
ferentiation as well as increased adipocyte triglyceride
content (Fig. 10D). The prolipogenic effects induced by
ML-193 and GPR55 silencing in cultured adipocytes
Figure 5. Effects of GPR55 deﬁciency upon key modulators of insulin signaling. Lysates prepared from epididymal fat tissue (A),
liver (B), and gastrocnemius muscle (C) in WT and GPR552/2 mice were immunoblotted using the antibodies against IRb
(insulin receptor b subunit), IRS-1, PDK1, protein phosphatase 2A (PP2A), and PTEN. Values presented are the means 6 SEM
from 4 individual animals (n = 5 for liver samples). *P , 0.05.
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are consistent with the effects of GPR55 deficiency on
adiposity in vivo, with further work required to establish
precisely how receptor blockade mechanistically links to
regulation of adipogenic genes.
DISCUSSION
The data presented herein show for the first time that
agonist-induced GPR55 activation augments insulin sig-
naling in cultured rat myotubes, murine 3T3-L1 adipo-
cytes, rat H4IIE, and humanHepG2 liver cells and that, in
rat skeletal muscle cells, GPR55 activation induces its own
receptor expression. We also highlight that GPR55 de-
ficiency in mice is associated with not only increased ex-
pression of lipogenic proteins in adipose tissue, but with
significant dysfunction in insulin signaling in adipose tis-
sue, liver, and skeletalmuscle. The lattermayarise, in part,
through elevated expression/activity of PTEN in adipose
tissue and liver and as a consequence of reduced IRS-1
expression in muscle. Precisely how PTEN abundance is
up-regulated inadipose tissueand liverofGPR552/2mice
is unclear, but it may involve transcripitional and/or
posttranslational mechanisms (41). The PTEN gene pro-
moter is aknown target forPPARg,whichhasbeen shown
to induce PTEN expression in inflammatory and tumor-
derived cells (42). Because PPARg is up-regulated in adi-
pose tissueofGPR55-deficientmice, thismayhelpenhance
PTEN expression. Alternatively, reduced ubiquitination/
degradation of PTENmay account for its increased tissue
abundance (43). Very little is known about the E3-ligases
that ubiquitinate PTEN or whether they are downstream
targets for GPR55 signaling. In any event, themechanisms
increasing PTEN gene expression and/or protein stability
in adipose tissue and liver need not be exclusive because
both would facilitate greater hydrolysis of membrane PI
(3,4,5)P3 to PI(4,5)P2 and lower PKB activation at the
plasma membrane (44). PTEN abundance was unaltered
in skeletal muscle of GPR552/2 mice, and, although the
reasons for this remain unclear, it may in part be due to
the much lower expression of PPARg in skeletal mus-
cle vis-a`-vis adipose tissue (45). By contrast, muscle of
Figure 6. Conﬁrmation of GPR55 expression in rat and human skeletal muscle and in cultured rat myotubes and that in myotubes
modulation of GPR55 affects insulin signaling. A–C) Detection of GPR55 mRNA was performed using RT-PCR analysis in rat
skeletal L6 myoblasts (Mb) (A) and differentiated L6 myotubes (Mt) (A, C), rat soleus (A), and human myotubes (B). The
induction of GPR55 mRNA in L6 myotubes after treatment with LPI (3 mM for 48 h) was also determined by conventional RT-
PCR analysis (representative of 3 independent experiments) (C). D, E) For insulin signaling studies, L6 myotubes were treated
with 3 mM LPI, 3 mM O-1602, and/or 5 mM O-1918 for 48 h prior to stimulation with insulin (20 nM for 10 min) or vehicle
control. Resulting cell lysates were immunoblotted with antibodies against phospho-ERK1/2 and phospho-CREB (D) or phospho-
PKBT308 (E). Values presented are the mean 6 SEM from 3 independent experiments. *P , 0.05 between the indicated bars.
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GPR55-deficient mice has less IRS-1, which is unlikely to
be accounted for by changes in gene transcription because,
in separate studies, we observe no differences in IRS-1
mRNA content in WT or GPR552/2 muscle (data not
shown).Muscle IRS-1 abundance is known tobe regulated
by the ubiquitin-proteosome system (46), but whether this
is influenced by GPR55-mediated signaling is not known.
Nonetheless, much like the increase in adipose and liver
PTEN in GPR552/2 mice, loss of muscle IRS-1 reduces
insulin signaling capacity (Fig. 4C, D).
The impaired insulin signaling in skeletal muscle, adi-
pose tissue, and liver of GPR552/2 mice implies that
GPR55 may normally function to help sustain and/or
enhance insulin action in these tissues. The finding that
established cell lines that have been used extensively as in
vitro models of these tissues express GPR55 and that O-
1602 and LPI enhance PKB and MAP-kinase directed
insulin signaling is fully congruent with this view. More-
over, the observation that the stimulatory effects of LPI on
insulin signaling are lost upon silencingGPR55 expression
in L6 muscle cells or upon incubation of cells with 3
structurally distinct GPR55 antagonists (O-1918, CID, and
ML-193) provides strong evidence that GPR55 activation
acts positively on insulin action in the cells we have
studied. How might such regulation be exerted? GPR55
is known to couple to Ga12/13 and Gq proteins, which,
depending on cell type and context, can potentially link to
and activate multiple signaling pathways (47). Some of
these pathways invoke an increase in cytosolic calcium,
activation of MAP kinases, and activation of small G
Figure 7. Augmentation of insulin signaling in response to GPR55 activation can be blocked by ML-193 and by shRNA-mediated
receptor silencing in L6 myotubes. A, B) L6 myotubes were treated with 3 mM LPI in the presence or absence of 20 mM ML-193
(A) or 20 mM CID16020046 (B) (GPR55 antagonists) as indicated for 48 h prior to stimulation with insulin (20 nM for 10 min) or
vehicle control prior to cell lysis. Resulting cell lysates were immunoblotted with antibodies against phospho-PKBT308 and PKB.
C) GPR55 mRNA expression in L6 myotubes infected with lentiviral constructs containing a non-target control shRNA or GPR55
shRNA. D, E) Effects of 3 mM LPI (D) and 10 mM 1-(2,4-diﬂuorophenyl)-5-[[2-[[(1,1-dimethylehyl)amino]thioxomethyl]
hydrazinylidene]methyl]-1H-pyrazole-4-carboxylic acid methyl ester (ML-184) (E) (GPR55 agonist) on insulin signaling (phospho-
PKBS473) in control (nontarget shRNA) infected myotubes and myotubes in which GPR55 had been silenced (GPR55 shRNA). F)
IRS-1 protein abundance in control and GPR55-silenced L6 myotubes was determined by immunoblotting as indicated. NS, not
signiﬁcant. The bar values presented are the means6 SEM from at least 3 independent experiments. *P, 0.05 between the indicated bars.
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proteins such as RhoA, which may then act to mechanis-
ticallymodulate insulin signaling components and/or key
transcriptional networks, such as those regulated by
CREB, NFAT, and NF-kB (47). Activation of RhoA by
GPR55would increase activity of its associated ROCK1, a
Ser/Thr kinase that has been shown to support insulin
signaling in skeletal muscle by promoting phosphoryla-
tion of IRS-1–Ser632/635 (48). Increased phosphoryla-
tion of these residues enhances IRS-1–PI3K association,
whereas mice lacking ROCK1 not only exhibit reduced
phosphorylation of these serine residues but also display
impaired insulin-stimulated IRS-1–associated PI3K activ-
ity and blunted phosphorylation of PKB and that of its
downstream targets, such as AS160 (48). Consistent with
these findings and the observed impairment in insulin
signaling in skeletal muscle of GPR552/2mice, we reveal
that ROCK1 protein abundance is significantly reduced in
gastrocnemius muscle of mice lacking GPR55, coinciding
with reduced phosphorylation of the ROCK substrate
MYPT1 at Thr696 (Supplemental Fig. 3). Whether the
GPR55-RhoA-ROCK1 axis supports LPI-induced increase
in insulin signaling in our in vitro cell models or whether
loss of receptor coupling to RhoA-ROCK1 in GPR552/2
mice contributes to the dysfunctional insulin signaling
(alongside tissue-specific changes in PTEN and IRS-1) in
vivo remains to be investigated.
Our observation that GPR55-deficient mice exhibit re-
duced physical activity and energy expenditure is consis-
tent with the recent findings of Meadows et al. (30),
who also reported a significant decline in spontaneous
locomotor and voluntary activity in GPR552/2 mice.
These authors concluded that because treadmill exercise
revealed no differences in exercise capacity between WT
and GPR552/2 mice, the decline in physical activity was
more likely a consequence of reduced “brain-driven”
motor functions and/or motivation rather than defects in
muscle function per se (30). However, unlike this latter
studywe also detected amodest reduction in leanmass of
GPR552/2mice (;9%at22wkofage). The reasons for this
discrepancy are unclear, but our findings imply that
GPR55 signaling may normally confer a beneficial stimu-
lus in maintaining mass of lean tissues, such as skeletal
Figure 8. Conﬁrmation of GPR55 expression in differentiated murine 3T3-L1 adipocytes, rat H4IIE, and human HepG2
hepatoma cells and effects of GPR55 modulation in these cells on insulin signaling. Expression of GPR55 in 3T3-L1 adipocytes
(A), rat H4IIE liver cells (B), and human HepG2 hepatoma cells (C) was determined by conventional RT-PCR analysis
(representative of 3 independent experiments). Cells were treated for 24 h with 3 mM LPI, 10 mM ML-193, and/or 10 mM
CID16020046 (CID) as indicated prior to stimulation with insulin (20 nM for 10 min) or vehicle control. Resulting cell lysates
were immunoblotted using the antibodies against phospho-PKBT308 or phospho-PKBS473. Values presented are means6 SEM from
3 independent experiments. *P , 0.05 between the indicated bar values.
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muscle and heart. It is conceivable that the reduced
physical/muscular activity associated with decline in
central motor function in GPR55-deficient mice serves
as a pervasive, albeit indirect, atrophic stimulus (49).
However, it is also plausible that, because lean tissue
mass is critically dependent upon protein turnover, the
impaired insulin sensitivity we observe in GPR552/2
tissues such as skeletal muscle (a major component of
lean body mass) may have direct effects upon protein
metabolism. Insulin conveys a permissive stimulus for
muscle protein synthesis and actively represses protein
breakdown in this tissue (50). Consequently, reduced
insulin sensitivity of GPR55-deficient muscle may
contribute to a decline in its mass. The small decline in
total muscle protein in the gastrocnemius is supportive
of this idea. However, we have previously shown that
hearts of mature GPR552/2 mice exhibit a marked re-
duction in left ventricular wall thickness compared
with age-matched WT mice, and, as such, this loss
in cardiac muscle is associated with significant sys-
tolic dysfunction (51). Future studies using a targeted
conditional GPR55 knockout strategy may prove in-
structive in helping to define the role that central and
peripheral receptor expression plays in maintaining
mass, integrity, and function of specific lean tissues
such as skeletal muscle and heart.
Unlike the data presented herein and data reported by
Meadows et al. (30), a more recent publication by Bjursell
et al. (52) reported that the tendency of GPR55-deficient
mice toward increased obesity was not statistically sig-
nificant in their study. The reasons for this apparent in-
congruity remain unclear, but our analysis indicates that
the increase in fat mass of GPR552/2 mice cannot be at-
tributed to greater food intake or, as others have shown
(30), to changes in orexigenic and/or anorexigenic neu-
ropeptide expression. However, a sustained reduction
in physical activity and energy expenditure would be
expected to shift the energybalancewith timeandfavor fat
gain with a consequential increase in body weight. The
finding that increased adiposity is a feature more prom-
inent in agedGPR552/2micewouldbe entirely consistent
with such a proposition (52).
Figure 9. Effects of sustained GPR55 antagonism using ML-193 on adipocyte differentiation/lipogenic markers and triglyceride
accumulation. Fully conﬂuent 3T3-L1 adipocytes were allowed to differentiate for up to 10 d in the presence or absence of ML-193
(10 mM). On the indicated days, relative mRNA abundance of PPARg, FAS, and FABP4 (A) as well as triglyceride (C) content were
determined. Immunoblot analysis was performed to determine protein levels of perilipin, FAS, acetyl CoA carboxylase (ACC),
FABP4, and Actin (as an internal control) in 3T3-L1 adipocytes differentiated for 6 d in the presence or absence of ML-193 (10 mM)
(B). All quantiﬁed values presented are the means 6 SEM from 3 independent experiments. *P , 0.05 between the indicated bars.
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In addition to the reduced energy expenditure, our
study reveals that increased fatmass in GPR552/2mice
may also be driven by greater expression of lipogenic
genes in adipose tissue potentially linking GPR55 sig-
naling inmice as a repressor of lipogenesis/adipogenesis.
This notion is further strengthened by our novel finding
that chronic antagonism of GPR55 in differentiating 3T3-
L1 adipocytes results in the induction of adipogenic genes
and those implicated in fat synthesis/accumulation. In-
deed, the demonstration that GPR55 inactivation is asso-
ciated with greater triglyceride accumulation in cultured
murine adipocytes is fully consistent with this observa-
tion and implies that GPR55 activitymay function to help
restrain increases in adiposity. However, somewhat par-
adoxically, GPR55 expression has been shown to posi-
tively correlate with obesity in human adipose tissue,
and, although the effects of LPI on insulin signaling in
human fat were not studied, LPI induced expression of
lipogenic genes when incubated ex vivo with visceral, but
not subcutaneous, fat explants (29). Moreover, in our
study LPI treatment caused a slight, although not signifi-
cant, reduction in lipogenic gene expression and cellular
triglyceride accumulation in 3T3-L1 adipocytes during
differentiation (Supplemental Fig. 4). It remains unclear
whether increased expression of GPR55 in visceral fat is
a cause or consequence of obesity or if the stimulatory
effects of LPI on fat genes can be repressed by selective
GPR55 receptor antagonists. It is difficult to reconcile
why human and mouse GPR55 may impose divergent
effects upon adipose tissue because no compelling ev-
idence of differences in ligand pharmacology or re-
ceptor signaling exists among the 2 species. Indeed, this
issue is further confounded by the finding that activa-
tion of human or rodent GPR55 in other cell or tissue
types, such as isolated pancreatic islets or, as shown in
the current study, HepG2 (a human-derived liver cell
line) and H4IIE (a rat-derived cell line), can elicit very
similar effects upon insulin secretion (28) and insulin
signaling, respectively. Consequently, further analysis
of how GPR55 agonists/antagonists specifically mod-
ify the biology andmetabolism of human adipose tissue
that is free of infiltrating nonfat cell types such as
macrophages, which not only express GPR55 but also
exhibit lipid accumulation when the receptor is acti-
vated (53), is clearly warranted for further clarification
of this issue.
Figure 10. Effects of sustained GPR55 silencing on adipocyte differentiation/lipogenic markers and triglyceride accumulation.
After transfection with control or GPR55-trageting siRNA, 3T3-L1 adipocytes were allowed to differentiate for up to 10 d. A)
GPR55 mRNA abundance was determined in control and GPR55 siRNA-transfected 3T3-L1 adipocytes by qPCR analysis. B–D)
On the indicated days of differentiation, relative mRNA abundance of FAS (B), PPARg (C), and triglyceride (D) content were
determined. All quantiﬁed values presented are mean + SEM from 3 independent experiments. *P , 0.05 between the indicated bars.
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CONCLUSIONS
The current study shows that GPR55 deficiency in mice is
not only associated with increased adiposity, reduced
physical activity, and energy expenditure but that adipose
tissue, liver, and skeletal muscle exhibit a significant re-
duction in insulin signaling capacity, which may be a con-
sequence of tissue-specific changes in PTEN and IRS-1
expression. The notion that GPR55 may regulate insulin
action is further strengthened by our finding that recep-
tor activation in 4 different cells lines augments insulin
signaling and that this response can be negated by 3 struc-
turally distinct GPR55 antagonists or by genetically silenc-
ing receptor expression in myotubes. Collectively, our
observations indicate that therapeutic modulation of pe-
ripheralGPR55activitymayprovideameans for countering
obesity-linked metabolic dysfunction and insulin resistance
and improving the metabolic status of such tissues.
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